NASDAQ:BCDA BioCardia Q1 2026 Earnings Report $1.10 -0.03 (-2.65%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$1.14 +0.04 (+3.64%) As of 05/5/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast BioCardia EPS ResultsActual EPSN/AConsensus EPS -$0.17Beat/MissN/AOne Year Ago EPSN/ABioCardia Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABioCardia Announcement DetailsQuarterQ1 2026Date5/13/2026TimeAfter Market ClosesConference Call DateWednesday, May 13, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile BioCardia Earnings HeadlinesBioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy ...April 28, 2026 | finance.yahoo.comBioCardia Gains Key Japanese Regulatory Support for CardiAMPApril 20, 2026 | tipranks.comYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners guide...please take a few seconds and download it right now before your download link expires. That way, no matter what it costs in the future, you'll have a free copy on your computer. | Profits Run (Ad)BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart FailureApril 20, 2026 | globenewswire.comBioCardia (BCDA) price target decreased by 38.00% to 15.81April 10, 2026 | msn.comBioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart FailureApril 2, 2026 | markets.businessinsider.comSee More BioCardia Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioCardia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioCardia and other key companies, straight to your email. Email Address About BioCardiaBioCardia (NASDAQ:BCDA) is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle. The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System. The Helix system is designed to facilitate precise, minimally invasive delivery of cells and biologics into viable myocardium. CardiAMP is an autologous bone marrow-derived progenitor cell therapy under investigation for its potential to improve cardiac function in patients with ischemic heart failure. Both platforms have secured investigational device exemptions from the U.S. Food and Drug Administration and are being evaluated in multi-center clinical trials. Founded in the mid-2000s and headquartered in the San Francisco Bay Area, BioCardia has assembled a leadership team with deep expertise in interventional cardiology, regenerative medicine, and medical device development. Gary S. Margulies, M.D., serves as President and Chief Executive Officer, guiding the company’s clinical programs and strategic partnerships. BioCardia collaborates with academic medical centers and clinical research organizations across the United States to advance its pipeline and ultimately bring new therapeutic options to patients suffering from heart disease.View BioCardia ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in MayNebius Breaks Out to All-Time Highs—Here's What's Driving It.3 Reasons Analysts Love DexComMonolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Upcoming Earnings AppLovin (5/6/2026)ARM (5/6/2026)DoorDash (5/6/2026)Fortinet (5/6/2026)Marriott International (5/6/2026)Warner Bros. Discovery (5/6/2026)Apollo Global Management (5/6/2026)Cencora (5/6/2026)Cenovus Energy (5/6/2026)CVS Health (5/6/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
